Chickenpox Vaccine Market Report 2026

Chickenpox Vaccine Market Overview

• Chickenpox Vaccine market size has reached to $3.76 billion in 2025 • Expected to grow to $5.12 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: Rising Awareness Fuels Demand For Growth In Chickenpox Vaccine Market • Market Trend: Technological Advancements in the Chickenpox Vaccine Market to Enhance Immunization Efficacy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chickenpox Vaccine Market?

Chickenpox vaccines are biological preparations that stimulate the cell-mediated immune response and prepare it to fight future infections caused by viruses by triggering IgG-mediated production of antibodies against varicella-zoster-specific pathogens that enter the body. The varicella-zoster virus causes chickenpox, which is a highly contagious disease (VZV). The main types of chickenpox vaccine include monovalent varicella vaccine and combination varicella vaccine. The monovalent varicella vaccine comprises a live, attenuated virus that is so immunogenic that one dose induces antibody formation in 97% of school-aged vaccines. Their various applications include mumps, measles, rubella, varicella immunization, herpes zoster immunization, and chickenpox vaccination and various end-users such as hospitals, clinics, and others.

What Is The Chickenpox Vaccine Market Growth Forecast?

The chickenpox vaccine market size is expected to see strong growth in the next few years. It will grow to $5.12 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to rising government funding for immunization programs, introduction of combination vaccines (MMRV), increasing pediatric healthcare access in emerging economies, advancements in vaccine delivery technologies, growing public-private partnerships in healthcare. Major trends in the forecast period include increasing adoption of pediatric vaccination programs, rise in combination vaccines for varicella, development of live attenuated varicella vaccines, expansion of immunization coverage in emerging markets, growing awareness about preventive healthcare.

Global Chickenpox Vaccine Market Segmentation

1) By Vaccine: Monovalent Varicella Vaccine, Combination Varicella Vaccine 2) By Application: Mumps, Measles, Rubella, And Varicella Immunization, Herpes Zoster Immunization, Chickenpox Vaccination 3) By End-Users: Hospitals, Clinics, Other End-Users

What Is The Driver Of The Chickenpox Vaccine Market?

The increasing awareness about the benefits of vaccination is expected to propel the growth of the chickenpox vaccine market going forward. A vaccination, in simplest terms, is a medical procedure that introduces weakened or inactive forms of a virus or bacteria into the body. Increased awareness of the chickenpox vaccine helps ensure higher vaccination rates, reducing the overall incidence of the disease. For instance, in November 2023, according to the UK Health Security Agency (UKHSA), a UK-based government agency, in 2023 survey, about 86% of parents agreed that “vaccines work,” 80% said they are safe, and 78% said they trust vaccines. Therefore, the increasing awareness about the benefits of vaccination is driving the growth of the chickenpox vaccine industry.

Key Players In The Global Chickenpox Vaccine Market

Major companies operating in the chickenpox vaccine market are Merck & Co., Sanofi Pasteur, Takeda Pharmaceutical Company Limited, CSL Limited, Pfizer Inc., Seqirus, Serum Institute of India Pvt. Ltd., Bharat Biotech, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co., Ltd., Chongqing Zhifei Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., Adimmune Corporation, Biological E. Limited, Walvax Biotechnology Co., Ltd., Zydus Cadila, Indian Immunologicals Ltd., Panacea Biotec Ltd., Bio Farma, PT Kalbe Farma Tbk, CanSino Biologics

Global Chickenpox Vaccine Market Trends and Insights

Major companies operating in the chickenpox vaccine market are focusing on technological advancements, such as two-dose live attenuated varicella vaccines, to meet the rising demand for improved immunization efficacy and reduced breakthrough infections. A two-dose live attenuated vaccine involves administering two spaced doses of a weakened varicella-zoster virus, offering stronger and longer-lasting immunity compared to the traditional single-dose approach. For instance, in September 2025, SK bioscience, a South Korea–based biotechnology company, launched SKYVaricella in a two-dose clinical advancement pathway, an innovative next-generation varicella vaccine introduced after 2022. SKYVaricella is a lyophilized live-attenuated varicella vaccine formulated using the Oka strain, reconstituted before injection, and designed to stimulate robust immune responses. It features enhanced safety profiling, improved antibody persistence, and suitability for large-scale immunization programs. The vaccine aims to reduce breakthrough varicella cases, align with updated global immunization recommendations, and expand preventive coverage across pediatric populations.

What Are Latest Mergers And Acquisitions In The Chickenpox Vaccine Market?

In August 2023, GPN Vaccines Inc., a South Korea-based provider of vaccine development and manufacturing services, completed the acquisition of BacVax Inc. for an undisclosed amount. With this acquisition, GPN Vaccines aimed to strengthen its pipeline and expand its portfolio of vaccines, including those for varicella (chickenpox), to enhance its global market presence. BacVax Inc. is a US-based company that specializes in vaccine development, focusing on innovative platforms for infectious diseases, including varicella vaccines.

Regional Insights

North America was the largest region in the chickenpox vaccine market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chickenpox Vaccine Market?

The chickenpox vaccines market consists of sales of single-antigen varicella vaccines and mixed-antigen varicella vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chickenpox Vaccine Market Report 2026?

The chickenpox vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chickenpox vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.